<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34290285</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Rapid in vitro quantification of TDP-43 and FUS mislocalisation for screening of gene variants implicated in frontotemporal dementia and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>14881</StartPage><MedlinePgn>14881</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14881</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-94225-1</ELocationID><Abstract><AbstractText>Identified genetic mutations cause 20% of frontotemporal dementia (FTD) and 5-10% of amyotrophic lateral sclerosis (ALS) cases: however, for the remainder of patients the origin of disease is uncertain. The overlap in genetic, clinical and pathological presentation of FTD and ALS suggests these two diseases are related. Post-mortem, ~&#x2009;95% of ALS and ~&#x2009;50% of FTD patients show redistribution of the nuclear protein TDP-43 to the cytoplasm within affected neurons, while ~&#x2009;5% ALS and ~&#x2009;10% FTD show mislocalisation of FUS protein. We exploited these neuropathological features to develop an unbiased method for the in vitro quantification of cytoplasmic TDP-43 and FUS. Utilising fluorescently-tagged cDNA constructs and immunocytochemistry, the fluorescence intensity of TDP-43 or FUS was measured in the nucleus and cytoplasm of cells, using the freely available software CellProfiler. Significant increases in the amount of cytoplasmic TDP-43 and FUS were detectable in cells expressing known FTD/ALS-causative TARDBP and FUS gene mutations. Pharmacological intervention with the apoptosis inducer staurosporine and mutation in a secondary gene (CYLD) also induced measurable cytoplasmic mislocalisation of endogenous FUS and TDP-43, respectively. These findings validate this methodology as a novel in vitro technique for the quantification of TDP-43 or FUS mislocalisation that can be used for initial prioritisation of predicted FTD/ALS-causative mutations.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oyston</LastName><ForeName>Lisa J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ubiparipovic</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallupp</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccanfuso</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson-Stone</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia. carol.dobson-stone@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="C409984">CYLD protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D000074749">Deubiquitinating Enzyme CYLD</NameOfSubstance></Chemical><Chemical><RegistryNumber>H88EPA0A3N</RegistryNumber><NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074749" MajorTopicYN="N">Deubiquitinating Enzyme CYLD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34290285</ArticleId><ArticleId IdType="pmc">PMC8295343</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-94225-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-94225-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lillo P, Hodges JR. Frontotemporal dementia and motor neurone disease: Overlapping clinic-pathological disorders. J. Clin. Neurosci. 2009;16:1131&#x2013;1135. doi: 10.1016/j.jocn.2009.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2009.03.005</ArticleId><ArticleId IdType="pubmed">19556136</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919&#x2013;931. doi: 10.1016/S0140-6736(16)00737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front. Neurosci. 2020;14:1&#x2013;10. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C, et al. CYLD is a causative gene for frontotemporal dementia&#x2014;Amyotrophic lateral sclerosis. Brain. 2020;143:783&#x2013;799. doi: 10.1093/brain/awaa039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa039</ArticleId><ArticleId IdType="pmc">PMC7089666</ArticleId><ArticleId IdType="pubmed">32185393</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:1&#x2013;36. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 2011;121:207&#x2013;218. doi: 10.1007/s00401-010-0764-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0764-0</ArticleId><ArticleId IdType="pubmed">21052700</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol. 2007;114:5&#x2013;22. doi: 10.1007/s00401-007-0237-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0237-2</ArticleId><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 Mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;19:46&#x2013;64. doi: 10.1093/hmg/ddq137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Myotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Younes K, Miller BL. Frontotemporal dementia: Neuropathology, genetics, neuroimaging, and treatments. Psychiatr. Clin. North Am. 2020;43:331&#x2013;344. doi: 10.1016/j.psc.2020.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psc.2020.02.006</ArticleId><ArticleId IdType="pubmed">32439025</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q, et al. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J. Neurosci. 2014;34:7802&#x2013;7813. doi: 10.1523/JNEUROSCI.0172-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0172-14.2014</ArticleId><ArticleId IdType="pmc">PMC4044245</ArticleId><ArticleId IdType="pubmed">24899704</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, et al. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat. Commun. 2018;9:335. doi: 10.1038/s41467-017-02299-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02299-1</ArticleId><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, et al. ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS&#xa0;One. 2013;8:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843686</ArticleId><ArticleId IdType="pubmed">24312274</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JH, et al. ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. Exp. Cell Res. 2013;319:1998&#x2013;2005. doi: 10.1016/j.yexcr.2013.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2013.05.025</ArticleId><ArticleId IdType="pubmed">23742895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2009;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, et al. Cytoplasmic relocalization of TAR DNA-Binding Protein 43 is not sufficient to reproduce cellular pathologies associated with ALS in vitro. Front. Mol. Neurosci. 2017;10:1&#x2013;13. doi: 10.3389/fnmol.2017.00046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00046</ArticleId><ArticleId IdType="pmc">PMC5323424</ArticleId><ArticleId IdType="pubmed">28286471</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. 2013;110:E736&#x2013;E745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W, et al. Disease-associated mutations of TDP-43 promote turnover of the protein through the proteasomal pathway. Mol. Neurobiol. 2014;50:1049&#x2013;1058. doi: 10.1007/s12035-014-8644-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8644-6</ArticleId><ArticleId IdType="pubmed">24477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutihac R, et al. TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca2+ signaling in motor neurons. Neurobiol. Dis. 2015;75:64&#x2013;77. doi: 10.1016/j.nbd.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.010</ArticleId><ArticleId IdType="pubmed">25526708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Zhan L, Hanson KA, Tibbetts RS. High-content RNAi screening identifies the type 1 inositol triphosphate receptor as a modifier of TDP-43 localization and neurotoxicity. Hum. Mol. Genet. 2012;21:4845&#x2013;4856. doi: 10.1093/hmg/dds321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds321</ArticleId><ArticleId IdType="pmc">PMC3529575</ArticleId><ArticleId IdType="pubmed">22872699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, et al. Modeling of frontotemporal dementia using IPSC technology. Int. J. Mol. Sci. 2020;21:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7432206</ArticleId><ArticleId IdType="pubmed">32727073</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AE, et al. Cell Profiler: Image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100. doi: 10.1186/gb-2006-7-10-r100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2006-7-10-r100</ArticleId><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 2010;19:4160&#x2013;4175. doi: 10.1093/hmg/ddq335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq335</ArticleId><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008;63:535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv. Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, et al. Novel mutations in TARDBP(TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4:1&#x2013;8. doi: 10.1371/journal.pgen.1000193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000193</ArticleId><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignell GR, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 2000;25:160&#x2013;165. doi: 10.1038/76006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/76006</ArticleId><ArticleId IdType="pubmed">10835629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan N, Ashworth A. Inherited cylindromas: Lessons from a rare tumour. Lancet Oncol. 2015;16:e460&#x2013;e469. doi: 10.1016/S1470-2045(15)00245-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(15)00245-4</ArticleId><ArticleId IdType="pubmed">26370355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671&#x2013;675. doi: 10.1038/nmeth.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta JR, et al. Mutant human FUS is ubiquitously mislocalized and generates persistent stress granules in primary cultured transgenic zebrafish cells. PLoS&#xa0;One. 2014;9:e90572. doi: 10.1371/journal.pone.0090572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090572</ArticleId><ArticleId IdType="pmc">PMC4049593</ArticleId><ArticleId IdType="pubmed">24912067</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno F, et al. A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. Acta Neuropathol. Commun. 2015;3:1&#x2013;13. doi: 10.1186/s40478-015-0190-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0190-6</ArticleId><ArticleId IdType="pmc">PMC4382926</ArticleId><ArticleId IdType="pubmed">25853458</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416. doi: 10.1016/S1474-4422(08)70071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70071-1</ArticleId><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi E, van der Zee J, Turon Estrada A, Van Broeckhoven C, Sanchez-Valle R. TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy. Neuropathol. Appl. Neurobiol. 2014;40:225&#x2013;230. doi: 10.1111/nan.12063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12063</ArticleId><ArticleId IdType="pubmed">23692129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O, et al. Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms. DMM Dis. Model. Mech. 2018;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5897724</ArticleId><ArticleId IdType="pubmed">29419416</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianini M, et al. TDP-43 mutations link amyotrophic lateral sclerosis with R-loop homeostasis and R loop-mediated DNA damage. PLoS Genet. 2020;16:1&#x2013;23. doi: 10.1371/journal.pgen.1009260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1009260</ArticleId><ArticleId IdType="pmc">PMC7755276</ArticleId><ArticleId IdType="pubmed">33301444</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y-F, et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 2011;6:73. doi: 10.1186/1750-1326-6-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-73</ArticleId><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoka A, et al. TDP-43 M337V mutation in familial amyotrophic lateral sclerosis in Japan. Intern. Med. 2010;49:331&#x2013;334. doi: 10.2169/internalmedicine.49.2915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.49.2915</ArticleId><ArticleId IdType="pubmed">20154440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 2013;22:2676&#x2013;2688. doi: 10.1093/hmg/ddt117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt117</ArticleId><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett. 2008;582:2252&#x2013;2256. doi: 10.1016/j.febslet.2008.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.05.024</ArticleId><ArticleId IdType="pmc">PMC2478749</ArticleId><ArticleId IdType="pubmed">18505686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum. Mol. Genet. 2013;22:3112&#x2013;3122. doi: 10.1093/hmg/ddt166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt166</ArticleId><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, et al. The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo. Brain Res. 2016;1647:57&#x2013;64. doi: 10.1016/j.brainres.2016.04.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.069</ArticleId><ArticleId IdType="pmc">PMC5003772</ArticleId><ArticleId IdType="pubmed">27155453</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J. Biol. Chem. 2009;284:8516&#x2013;8524. doi: 10.1074/jbc.M809462200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809462200</ArticleId><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>